Abstracts Archive - Page 1561 of 2607 - ACR Meeting Abstracts

Abstract Number: 2606 • 2017 ACR/ARHP Annual Meeting
Pneumococcal Vaccination in Patients with Systemic Lupus Erythematosus: A Multicenter Placebo-Controlled Randomized Double-Blind Study
Sophie Grabar¹, Matthieu Groh², Mathilde Bahuaud³, Nathalie Costedoat-Chalumeau⁴, Veronique Le Guern⁵, Renato Fior⁶, Boris Bienvenu⁷, eric hachulla⁸, Mohamed Hamidou⁹, Jean Sibilia¹⁰, Alexis Mathian¹¹, Thomas Hanslik¹², Loïc Guillevin for the French Vasculitis Study Group¹³, Frédéric Batteux³ and Odile Launay¹⁴, ¹Université Paris Descartes, Sorbonne Paris Cité AP-HP, Unité de Biostatistique et Epidémiologie, Groupe Hospitalier Cochin Broca Hôtel-Dieu, Paris, France; INSERM, UPMC Université Paris 06, Institut Pierre Louis d’épidémiologie et de Santé Publique (IP, Paris, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ³Université Paris Descartes, Sorbonne Paris Cité AP-HP, Département d’Immunologie Biologique, Groupe Hospitalier Cochin Broca Hôtel-Dieu, Paris, France, Paris, France, ⁴Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ⁵Department of Internal Medicine, Department of Internal Medicine, Cochin University Hospital, Paris, France, ⁶Université Paris-Sud, AP-HP, Service de Médecine Interne et Immunologie Clinique, Hôpital Antoine Béclère, Clamart, France, Clamant, France, ⁷Internal Medicine, Hôpital de la côte de Nacre, Caen, France, ⁸chru lille hospital, lille, France, ⁹Medecine Interne, CHU Hôtel Dieu, Nantes, France, ¹⁰Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹¹Université Pierre et Marie Curie, Sorbonne Paris Cité AP-HP, Service de Médecine Interne 2, Centre de Référence National pour le Lupus et le Syndrome des Antiphospholipides, institut E3M, Paris, France, Paris, France, ¹²Université Versailles Saint-Quentin-en-Yvelines, APHP, Service de Médecine Interne, Hôpital Ambroise Paré, Boulogne-Billancourt, France, Boulogne-Billancourt, France, ¹³Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ¹⁴Université Paris Descartes, Sorbonne Paris Cité AP-HP, Groupe Hospitalier Cochin Broca Hôtel-Dieu, Fédération d'Infectiologie, Paris, France; Inserm, F-CRIN I-REIVAC., Paris, France
Background/Purpose: Invasive pneumococcal disease and respiratory tract infections are both frequent and severe in patients with systemic lupus erythematosus (SLE). This study aimed to compare…
Abstract Number: 2607 • 2017 ACR/ARHP Annual Meeting
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of BIIB059, a Monoclonal Antibody Targeting BDCA2 Following Administration of Intravenous and Subcutaneous Single or Multiple Doses in Healthy Volounters and Subjects with Active SLE
Himanshu Naik¹, Cristina Musselli¹, Catherine Barbey², Romy B. Christmann¹, Lauren Stevenson¹, Dania Rabah¹, Parul Gulati¹ and Nathalie Franchimont¹, ¹Biogen, Cambridge, MA, ²Biogen, Zug, Switzerland
Background/Purpose: BDCA2 is a plasmacytoid dendritic cell (pDC)-specific receptor that, upon activation, inhibits the production of inflammatory factors by human pDCs, including IFN-α a major…
Abstract Number: 2608 • 2017 ACR/ARHP Annual Meeting
Tacrolimus in Non-Asian Systemic Lupus Erythematosus Patients: A Real-Life Experience from Three European Centers
Chiara Tani¹, Miguel Martin-Cascon², Mériem Belhocine³, Roberta Vagelli¹, Chiara Stagnaro⁴, Guillermo Ruiz-Irastorza⁵, Nathalie Costedoat-Chalumeau³ and Marta Mosca¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Autoimmune Diseases Research Unit, BioCruces, Hospital Universitario Cruces, Barakaldo, Spain, ³Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ⁴Rheumatology Unit, University of Pisa, PISA, Italy, ⁵Autoimmune Diseases Research Unit, BioCruces, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: there is no consensus on the use of Tacrolimus (TAC) in patients with SLE; clinical studies on TAC, including all the RCT, are mostly…
Abstract Number: 2609 • 2017 ACR/ARHP Annual Meeting
A Systematic Literature Mining and Gene Expression Analysis Identifies Possible Drug Candidates for Repositioning in Lupus
Peter E. Lipsky, Matt Ryals, Adam Labonte, Sarah Heuer, James Dittman, Michelle Catalina and Amrie Grammer, AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA
Background/Purpose: Since new therapies for lupus have been extremely slow to develop and lupus patients have a great unmet medical need, an independent pharma-external effort…
Abstract Number: 2610 • 2017 ACR/ARHP Annual Meeting
Quantiferon Testing in a Clinical Trial of Systemic Lupus Erythematosus
Niti Goel¹, Stephen Wax², Amy Kao², Russell Reeve³ and Marsha Mackey⁴, ¹QuintilesIMS, Duke University School of Medicine, Durham, NC, ²EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA), Billerica, MA, ³QuintilesIMS, Durham, NC, ⁴QuintilesIMS, Rockville, MD
Background/Purpose: Tuberculosis (TB) has been reported to occur at a higher rate in SLE patients than in the general population. As a result, most clinical…
Abstract Number: 2611 • 2017 ACR/ARHP Annual Meeting
Walk SLE – a Pilot Study Exploring Walk with Ease (WWE), a Self-Directed Walking Program, in Lupus Patients
Brittaney-Belle E. Gordon¹, Katherine Kaufman², Sean T. Hicks¹, Julie A. Norfleet¹, Rebecca J. Cleveland¹, Leigh F. Callahan³ and Saira Z. Sheikh¹, ¹Thurston Arthritis Research Center, University of North Carolina School of Medicine, Chapel Hill, NC, ²Department of Pediatrics, Duke University School of Medicine, Durham, NC, ³Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Fatigue and arthritis are common sources of impairment in SLE patients that persist despite lifestyle and pharmacologic interventions. Walk with Ease (WWE) is the…
Abstract Number: 2612 • 2017 ACR/ARHP Annual Meeting
Disparities in Antimalarial Prescribing for Systemic Lupus Erythematosus Using a Real-World, Electronic Health Record
J.B. Boone, Wendy Xiong, Cecilia P. Chung, Leslie Crofford and April Barnado, Medicine, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Antimalarials (AMs) reduce disease activity and improve survival in patients with systemic lupus erythematosus (SLE) and are recommended regardless of disease severity. Prior studies…
Abstract Number: 2613 • 2017 ACR/ARHP Annual Meeting
Antimalarial Drug Toxicities in Rheumatic Skin Disease Patients
Lavanya Mittal¹, Lingqiao Zhang², Rui Feng² and Victoria Werth¹, ¹Department of Dermatology, Corporal Michael J. Crescenz VAMC, Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Although existing evidence demonstrates the efficacy of antimalarials for rheumatic skin disease, the safety of these medications, and particularly quinacrine, remain debated. Quinacrine may…
Abstract Number: 2614 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine Initiation Dosing Trends and Predictors in Systemic Lupus Erythematosus
April Jorge¹, Leo Lu², Yuqing Zhang³, Sharan K. Rai⁴, Lucy H. Young⁵, Ronald B. Melles⁶, Michael F. Marmor⁷, Karen H. Costenbader⁸, Rosalind Ramsey-Goldman⁹, S. Sam Lim¹⁰, John M. Esdaile¹¹, Ann E. Clarke¹², Murray Urowitz¹³, Anca Askanase¹⁴, Cynthia Aranow¹⁵, Michelle Petri¹⁶ and Hyon K. Choi⁴, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Department of Ophthalmology,, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ⁶Department of Ophthalmology, Kaiser Permanente, Redwood City, CA, ⁷Department of Ophthalmology and Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, ⁸Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁹FSM, Northwestern University, Chicago, IL, ¹⁰Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ¹¹Arthritis Research Canada, Richmond, BC, Canada, ¹²Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹³Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁴Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ¹⁵Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ¹⁶Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone of systemic lupus erythematosus (SLE) care. The major long-term adverse event risk is vision-threatening toxic retinopathy. The 2012 EULAR,…
Abstract Number: 2615 • 2017 ACR/ARHP Annual Meeting
Non-Pharmacological Treatment on Fatigue, Depression, Disease Activity, and Quality of Life of Systemic Lupus Erythematosus: A Systematic Review
Monthida Fangtham¹, Jacob Louis Nash², Stephanie Hyon³, Raveendhara R. Bannuru⁴ and Chenchen Wang³, ¹Internal Medicine, University of New Mexico, Albuquerque, NM, ²Health Sciences Library and Informatics Center, University of New Mexico, Albuquerque, NM, ³Rheumatology, Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA, ⁴Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA
Background/Purpose: In recent years, non-pharmacological therapies have been deemed as potentially beneficial for patients with systemic lupus erythematosus (SLE). These include complementary and integrative approaches,…
Abstract Number: 2616 • 2017 ACR/ARHP Annual Meeting
Mesenchymal Stem Cells Induce CD1c+ Tolerogenic Dendritic Cells Via up-Regulating FLT3L in Systemic Lupus Erythematosus
Xinran Yuan¹, Dandan Wang² and Lingyun Sun³, ¹Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology and immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ³Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital, Nanjing University Medical School, nanjing, China
Background/Purpose: Several tolerogenic dendritic cell (DC) subsets have been identified in human such as CD1c+ DCs, which could be elevated by injection of Flt-3 ligand…
Abstract Number: 2617 • 2017 ACR/ARHP Annual Meeting
Electrocardiogram Abnormalities Related to Antimalarials in Systemic Lupus Erythematosus
Taneisha McGhie¹, Paula Harvey², Jiandong Su¹, Nicole Anderson³, George A. Tomlinson⁴ and Zahi Touma⁵, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada
Background/Purpose: Anti-malarials (AM), such as hydroxychloroquine (HCQ) and chloroquine (CQ), have long been used for the treatment of systemic lupus erythematosus (SLE). However, despite their…
Abstract Number: 2618 • 2017 ACR/ARHP Annual Meeting
Why Aren’t All Patients with SLE Taking Hydroxychloroquine? A Retrospective Chart Review
Caroline H. Siegel¹, Jennifer M. Grossman¹, John Fitzgerald¹, Bevra H. Hahn^1,2, Lori Sahakian¹, Eloise Olmos² and Maureen A. McMahon¹, ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Although previous SLE treatment guidelines recommended judicious use of antimalarials, there is a growing body of evidence demonstrating that HCQ prevents flares, protects against…
Abstract Number: 2619 • 2017 ACR/ARHP Annual Meeting
Hemophagocytic Syndrome in Patients from SLE Registry from the Spanish Society of Rheumatology (RELESSER)
Ana Lois-Iglesias¹, Francisco J. de Toro², Antonio Zea³, María Galindo⁴, Esther Uriarte⁵, Iñigo Rúa-Figueroa⁶ and JM Pego-Reigosa⁷, ¹Rheumatology, University Hospital A Coruña, A Coruña, Spain, ²Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruna, Spain, ³Hospital Ramón y Cajal. Madrid, Madrid, Spain, ⁴Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ⁵Reumatología, Hospital de Donosti, Donosti, Spain, ⁶Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, ⁷Rheumatology Section, Hospital de Meixoeiro, Pontevedra, Spain, Vigo, Spain
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune systemic rheumatic disease that, in our area, presents hematologic manifestations in approximately 70% of cases1. Some of…
Abstract Number: 2620 • 2017 ACR/ARHP Annual Meeting
The Value of Repeat Biopsy in the Management of Lupus Nephritis Flares
Javier Narváez^1,2, Milagros Ricse², Montserrat Goma³, Francesca Mitjavila⁴, Xavier Fulladosa⁵, Olga Capdevila⁴, Joan Torras⁵, Xavier Juanola^2,6, Ramon Pujol⁴ and Joan Miquel Nolla², ¹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Pathology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Nephrology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Rheumatology, University Hospital Bellvitge, Barcelona, Spain
Background/Purpose: Whether a repeat renal biopsy is helpful during lupus nephritis (LN) flares remains debatable. Our objective was to analyze the clinical utility of repeat…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].